Yesterday Nebula Genomics announced it’s partnering with biopharmaceutical business EMD Serono, a Merck subsidiary. The aim is for EMD Serono to access anonymized genomic data for developing new drugs.
Nebula’s genome sequencing is stored in a conventional centralized system, but access and sharing of the data are controlled by individuals using blockchain.
Last year the company
raised a $4.3 million seed round from several venture capital companies including Khosla, Fenbushi Capital, and Mayfield.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
